Cerus (CERS)
(Delayed Data from NSDQ)
$2.04 USD
-0.01 (-0.49%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $2.03 -0.01 (-0.49%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
CERS 2.04 -0.01(-0.49%)
Will CERS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CERS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CERS
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
Neogen (NEOG) Lags Q4 Earnings Estimates
CERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates
Other News for CERS
Insider Selling: CFO Kevin Green Sells 82,657 Shares of Cerus Corp (CERS)
ZoomInfo Reports Weak Results, Joins Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
What You Missed On Wall Street This Morning
MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday
Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (OtherTKPHF), Cerus (CERS) and Ultragenyx Pharmaceutical (RARE)